Key Highlights

  • Retension Pharmaceuticals (NASDAQ:RTSN) amended its S-1 to offer 3.3 million shares at USD 11 to USD 13, which is about USD 39.6 million at the USD 12 midpoint, simple arithmetic on the terms.
  • Net proceeds are about USD 33.8 million at the midpoint, or about USD 39.4 million if underwriters exercise their 30-day option for 495,000 more shares in full.
  • The lead drug RTN-001 is a once-daily oral PDE-5 inhibitor for uncontrolled hypertension, with a Phase 2b trial begun in October 2025 and initial data expected in the first half of 2027.
  • Retension (NASDAQ:RTSN) held USD 13.493 million of cash at June 30, 2026 and reported a net loss of USD 7.5 million for the six months ended that date.

The Offering

Retension Pharmaceuticals plans to list on the Nasdaq Capital Market under the ticker RTSN. The amended S-1 offers 3,300,000 common shares at USD 11 to USD 13, with a 30-day option for the underwriters to buy 495,000 more. At the USD 12 midpoint, gross proceeds are about USD 39.6 million by simple arithmetic, and the filing puts net proceeds at about USD 33.8 million. The underwriters are Leerink Partners, Guggenheim Securities, Oppenheimer and Titan Partners. The IPO calendar expects the stock to trade on October 9, 2026, though pricing dates can slip. Retension (NASDAQ:RTSN) is a clinical-stage company, so the shares are priced on a drug candidate, not on sales.

The Drug and the Disease

RTN-001 is a once-daily oral PDE-5 inhibitor, the same drug class used in erectile dysfunction, being tested to lower blood pressure by relaxing blood vessels. The initial focus is uncontrolled hypertension, defined as blood pressure of 130/80 mmHg or higher despite two or more blood pressure medicines, with resistant hypertension as a second target. A Phase 2b dose-ranging trial began in October 2025, initial data are expected in the first half of 2027, and a Phase 3 trial is planned. That timeline means Retension (NASDAQ:RTSN) would need its proceeds to last through data that are still many months away, and a Phase 3 trial would require far more capital than this raise.

Risks and What to Watch

The numbers show why the raise matters. Cash of USD 13.493 million at June 30, 2026 compares with a net loss of USD 7.5 million for six months and USD 6.3 million, restated, for fiscal 2025, so the company needs new money to reach its data. Small IPOs often trade with wide swings and thin liquidity, and a single trial result can change the outlook sharply. Watch the final price, whether the underwriters take the option, how the shares trade on the first day and whether the company discloses its expected cash runway. With 10-year Treasury yields near 5.3%, risk appetite for small biotechs is not guaranteed. This is not Investment advice.

Where Things Stand

Retension (NASDAQ:RTSN) is raising about USD 39.6 million at the midpoint, with net proceeds of roughly USD 33.8 million, to fund a hypertension drug that has not yet reported Phase 2b data. The offering lifts a thin cash balance of USD 13.493 million, but the investment case rests on trial results expected in the first half of 2027. The balance of evidence is high risk and high uncertainty. The next catalyst is pricing, expected around October 9, 2026.